Improving bone marrow transplants and cell therapies for leukemia and lymphoma
Bone Marrow Grafting and Cellular Therapy for Leukemia and Lymphoma
['FUNDING_P01'] · STANFORD UNIVERSITY · NIH-11197504
New cell-based treatments and transplant methods aim to make bone marrow transplants safer and help people with leukemia or lymphoma avoid relapse.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-11197504 on ClinicalTrials.gov |
What this research studies
This program focuses on improving bone marrow transplants and cell therapies for people with leukemia and lymphoma. Researchers use animal models, detailed molecular and biological testing, advanced imaging, and coordinated clinical trials to learn how transplants work and why complications like graft-versus-host disease occur. They are testing new immune cell types — including iNKT cells, regulatory T cells, and CAR T cells — plus antibody strategies that target the stem cell antigen CD117 to prevent relapse. The work links lab studies with patient-focused clinical trials at Stanford to try to make transplants safer and more effective.
Who could benefit from this research
Good fit: People with leukemia or lymphoma who are eligible for hematopoietic cell transplantation or experimental cell therapy trials would be the main candidates.
Not a fit: People without blood cancers or those who are not eligible for transplants or cell therapy trials are unlikely to benefit directly from this program.
Why it matters
Potential benefit: If successful, the work could lower transplant risks, reduce graft-versus-host disease, and reduce relapse after transplant for people with blood cancers.
How similar studies have performed: Bone marrow transplant and CAR T-cell therapies have helped many patients, while some components of this program like iNKT and CD117-targeted strategies are newer and less proven.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NEGRIN, ROBERT S — STANFORD UNIVERSITY
- Study coordinator: NEGRIN, ROBERT S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases